Primary source Andelyn Biosciences: Andelyn Biosciences to Develop and Manufacture AAV Gene Therapy for Celliaz to Treat Retinitis Pigmentosa
Andelyn Biosciences, a cell and gene therapy contract development and manufacturing organization (CDMO) in Columbus, Ohio, announced on 12 November 2026 a partnership with Celliaz Co., Ltd., a South Korean biotechnology company. Andelyn will provide end-to-end development and manufacturing services for CLZ002, an investigational gene therapy built on an adeno-associated virus (AAV) vector.
What the release says about the manufacturing scope
- The program uses an AAV2 capsid, and Andelyn will manufacture it on its proprietary AAV Curator Suspension Platform.
- Celliaz will use the platform for AAV2 vector and plasmid manufacturing to support IND-enabling studies (the studies that precede a regulatory application to start clinical testing) and a planned Phase 1/2 trial.
- Celliaz’s chief executive cites Andelyn’s integrated plasmid and viral vector manufacturing capabilities as a reason for the choice.
- Andelyn’s chief commercial officer says the relationship adds to its work supporting multiple other South Korean programs.
About the CDMO
The release describes Andelyn as an FDA-inspected commercial CDMO with more than 20 years of experience, operating from development and manufacturing facilities in Columbus, Ohio. It states that Andelyn has produced clinical and commercial material for more than 500 cGMP batches and 85 global clinical trials, including an FDA-approved AAV gene therapy. It lists capabilities from plasmid engineering through process and analytical development to cGMP clinical and commercial manufacturing, for both suspension and adherent processes, and says these run on configurable, data-driven Curator platforms or by tech transfer within an established client program.
What the release does not say
The release gives no financial terms, batch scale, bioreactor volume, vector yield or timeline for IND-enabling work or the Phase 1/2 trial. It does not say where in Andelyn’s Columbus operations the work will run. This piece covers only the manufacturing arrangement, and takes no position on the therapy itself.
